CN112912075B - 治疗前列腺癌的组合疗法 - Google Patents

治疗前列腺癌的组合疗法 Download PDF

Info

Publication number
CN112912075B
CN112912075B CN201980059904.2A CN201980059904A CN112912075B CN 112912075 B CN112912075 B CN 112912075B CN 201980059904 A CN201980059904 A CN 201980059904A CN 112912075 B CN112912075 B CN 112912075B
Authority
CN
China
Prior art keywords
erg
etv1
compound
etv4
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980059904.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112912075A (zh
Inventor
莎拉·克里斯汀·艾特维
艾立克·坎珀
桑杰·拉霍堤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hengyi Biomedical Technology Shanghai Co ltd
Hengyi Biomedicine Shanghai Co ltd
Original Assignee
Hengyi Biomedical Technology Shanghai Co ltd
Hengyi Biomedicine Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hengyi Biomedical Technology Shanghai Co ltd, Hengyi Biomedicine Shanghai Co ltd filed Critical Hengyi Biomedical Technology Shanghai Co ltd
Publication of CN112912075A publication Critical patent/CN112912075A/zh
Application granted granted Critical
Publication of CN112912075B publication Critical patent/CN112912075B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201980059904.2A 2018-09-13 2019-09-13 治疗前列腺癌的组合疗法 Active CN112912075B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862730869P 2018-09-13 2018-09-13
US62/730,869 2018-09-13
US201862737612P 2018-09-27 2018-09-27
US62/737,612 2018-09-27
US201862778185P 2018-12-11 2018-12-11
US62/778,185 2018-12-11
PCT/US2019/050970 WO2020056232A1 (en) 2018-09-13 2019-09-13 Combination therapy for the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
CN112912075A CN112912075A (zh) 2021-06-04
CN112912075B true CN112912075B (zh) 2023-04-04

Family

ID=69778254

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980059904.2A Active CN112912075B (zh) 2018-09-13 2019-09-13 治疗前列腺癌的组合疗法

Country Status (12)

Country Link
US (1) US20220117942A1 (https=)
EP (1) EP3849544A4 (https=)
JP (1) JP7441214B2 (https=)
KR (1) KR102844523B1 (https=)
CN (1) CN112912075B (https=)
AU (1) AU2019338483B2 (https=)
CA (1) CA3112396A1 (https=)
IL (1) IL281281B2 (https=)
MX (1) MX2021002884A (https=)
SG (1) SG11202102492PA (https=)
TW (1) TWI816880B (https=)
WO (1) WO2020056232A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥（上海）股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法
US20220265618A1 (en) * 2021-02-22 2022-08-25 Celgene Quanticel Research, Inc. Methods of treating prostate cancer
CN114644687B (zh) * 2022-04-07 2023-06-27 华中科技大学同济医学院附属协和医院 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105407888A (zh) * 2013-06-21 2016-03-16 齐尼思表观遗传学公司 新双环溴结构域抑制剂
WO2016171470A1 (en) * 2015-04-21 2016-10-27 Kainos Medicine, Inc. Bromodomain-inhibiting compounds and methods to prevent or treat a cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2621483A1 (en) * 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2015065919A1 (en) * 2013-10-28 2015-05-07 The Regents Of The University Of California Treatment of metastatic prostate cancer
NO2719005T3 (https=) * 2014-07-28 2018-01-20
WO2017216772A2 (en) * 2016-06-16 2017-12-21 The University Of Chicago Methods and compositions for treating breast and prostate cancer
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
WO2018106433A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105407888A (zh) * 2013-06-21 2016-03-16 齐尼思表观遗传学公司 新双环溴结构域抑制剂
WO2016171470A1 (en) * 2015-04-21 2016-10-27 Kainos Medicine, Inc. Bromodomain-inhibiting compounds and methods to prevent or treat a cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation;Pingzhao Zhang et al.，;《Nat Med.》;20170930;第23卷(第9期);第1055-1062页 *
T-bet的生物学特性和研究进展;王珏等;《现代生物医学进展》;20130930;第13卷(第25期);第4995-4998页 *

Also Published As

Publication number Publication date
AU2019338483A1 (en) 2021-04-08
IL281281B1 (en) 2025-11-01
JP7441214B2 (ja) 2024-02-29
JP2022500431A (ja) 2022-01-04
KR20210060515A (ko) 2021-05-26
EP3849544A1 (en) 2021-07-21
MX2021002884A (es) 2021-07-15
AU2019338483B2 (en) 2025-01-02
TWI816880B (zh) 2023-10-01
EP3849544A4 (en) 2022-06-08
CA3112396A1 (en) 2020-03-19
SG11202102492PA (en) 2021-04-29
US20220117942A1 (en) 2022-04-21
IL281281B2 (en) 2026-03-01
KR102844523B1 (ko) 2025-08-12
TW202017926A (zh) 2020-05-16
CN112912075A (zh) 2021-06-04
WO2020056232A1 (en) 2020-03-19
IL281281A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CN112912077B (zh) 用于治疗三阴性乳腺癌的组合疗法
TWI874925B (zh) 癌症治療
CN112912075B (zh) 治疗前列腺癌的组合疗法
TW201138764A (en) Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents
CN103917514B (zh) 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法
CN118574617A (zh) 使用ptpn11抑制剂和kras g12c抑制剂的组合疗法
CN112912078B (zh) 用于治疗雌激素受体阳性乳腺癌的组合疗法
HK40053354B (en) Combination therapy for the treatment of prostate cancer
HK40053354A (en) Combination therapy for the treatment of prostate cancer
EA044198B1 (ru) Комбинированная терапия для лечения рака предстательной железы
JP2021527119A (ja) 塩形態
TW202327594A (zh) 用ｂｅｔ溴結構域抑制劑和ｐａｒｐ抑制劑的組合治療預選患者群體的三陰性乳腺癌的方法
CN121013721A (zh) 包含kras抑制剂和sph2抑制剂的组合疗法
HK40054127A (en) Combination therapy for the treatment of triple-negative breast cancer
HK40053731A (en) Combination therapy for the treatment of estrogen-receptor positive breast cancer
EA043826B1 (ru) Комбинированная терапия для лечения трижды негативного рака молочной железы
JP2011231023A (ja) 浸潤抑制剤
HK1198440B (en) Treatment of diseases and disorders related to transducin beta-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053354

Country of ref document: HK

CB02 Change of applicant information

Address after: 201203 building 10, No. 860, Xinyang Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant after: Hengyi biomedicine (Shanghai) Co.,Ltd.

Address before: Room 413, building 3, 1690 Cailun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant before: Hengyi biomedical technology (Shanghai) Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant